Clinical Trial Update: A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating JMT101 in combination with osimertinib versus osimertinib alone as first-line therapy for locally advanced or metastatic non…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• JMT101
• Osimertinib (osimertinib)

Snippet

Sponsor: Shanghai JMT-Bio Inc. | Conditions: Locally Advanced or Metastatic Non-squamous NSCLC, Harboring EGFR Sensitive Mutations NSCLC | Phase 3 | Status: RECRUITING